The Food and Drug Administration said it approved Qalsody to treat patients with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene. Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Cantor thinks M&A premium ‘baked into’ TG Therapeutics shares will increase
- Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48
- Biogen reports Q1 EPS $3.40, consensus $3.28
- Biogen price target raised to $300 from $295 at BofA